Claudia Proto

4.0k total citations
93 papers, 1.2k citations indexed

About

Claudia Proto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Claudia Proto has authored 93 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Oncology, 58 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Claudia Proto's work include Lung Cancer Treatments and Mutations (38 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (24 papers). Claudia Proto is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Lung Cancer Research Studies (24 papers). Claudia Proto collaborates with scholars based in Italy, United States and Spain. Claudia Proto's co-authors include Marina Chiara Garassino, Giuseppe Lo Russo, Diego Signorelli, Monica Ganzinelli, Filippo de Braud, Giulia Galli, Martina Imbimbo, Roberto Ferrara, Nicoletta Zilembo and Guido Levi and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Claudia Proto

90 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Claudia Proto Italy 18 780 531 213 171 150 93 1.2k
Elizabeth Dudnik Israel 19 817 1.0× 717 1.4× 221 1.0× 84 0.5× 185 1.2× 69 1.2k
Abdul Rafeh Naqash United States 18 1.3k 1.6× 479 0.9× 224 1.1× 180 1.1× 72 0.5× 103 1.5k
Florian Kocher Austria 18 498 0.6× 357 0.7× 215 1.0× 116 0.7× 160 1.1× 72 990
Meredith K. Chuk United States 14 429 0.6× 260 0.5× 175 0.8× 105 0.6× 116 0.8× 29 858
Motohiro Tamiya Japan 23 1.2k 1.6× 1.3k 2.4× 317 1.5× 126 0.7× 189 1.3× 163 1.9k
Hazem El‐Osta United States 16 434 0.6× 234 0.4× 262 1.2× 77 0.5× 109 0.7× 35 893
Sung Hoon Sim South Korea 18 493 0.6× 325 0.6× 243 1.1× 60 0.4× 230 1.5× 81 1.0k
Sukhbinder Dhesy‐Thind Canada 17 842 1.1× 263 0.5× 156 0.7× 107 0.6× 299 2.0× 50 1.3k
Aurélien Gobert France 8 869 1.1× 416 0.8× 235 1.1× 49 0.3× 70 0.5× 20 1.2k

Countries citing papers authored by Claudia Proto

Since Specialization
Citations

This map shows the geographic impact of Claudia Proto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Proto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Proto more than expected).

Fields of papers citing papers by Claudia Proto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Proto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Proto. The network helps show where Claudia Proto may publish in the future.

Co-authorship network of co-authors of Claudia Proto

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Proto. A scholar is included among the top collaborators of Claudia Proto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Proto. Claudia Proto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Proto, Claudia, Giuseppe Lo Russo, Arsela Prelaj, et al.. (2025). Tracking the Response to Immunotherapy: Blood microRNA Dynamics in Patients With Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 9(9). e2400790–e2400790. 1 indexed citations
3.
Proto, Claudia, Arsela Prelaj, Laura Mazzeo, et al.. (2025). 40P: Metformin plus/minus cyclic fasting mimicking diet to improve the efficacy of first-line chemo-immunotherapy in advanced LKB1-inactive NSCLC: Results of the phase II trial FAME. Journal of Thoracic Oncology. 20(3). S36–S37. 1 indexed citations
4.
Miceli, Rosalba, Hanna Eriksson, Giuseppe Lo Russo, et al.. (2024). Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study. Acta Oncologica. 63. 213–219. 3 indexed citations
5.
Occhipinti, Mario, Marta Brambilla, Raimondo Di Liello, et al.. (2024). Unleashing precision: A review of targeted approaches in pleural mesothelioma. Critical Reviews in Oncology/Hematology. 203. 104481–104481. 6 indexed citations
6.
Neal, Joel W., Armando Santoro, María González‐Cao, et al.. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports. 5(10). 100666–100666. 2 indexed citations
7.
Lorenzini, Daniele, A. Bassetti, Elena Tamborini, et al.. (2024). Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases. Clinical Lung Cancer. 26(1). e11–e17. 1 indexed citations
8.
Lorenzini, Daniele, Mario Occhipinti, Sara Manglaviti, et al.. (2023). 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib. Annals of Oncology. 34. S779–S779. 1 indexed citations
9.
Lococo, Filippo, Alessandra Cancellieri, Marco Chiappetta, et al.. (2023). Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. Clinical Lung Cancer. 24(5). 467–473. 4 indexed citations
10.
Capone, Iolanda, Fabio Bozzi, Gian Paolo Dagrada, et al.. (2022). Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples. SHILAP Revista de lepidopterología. 3(5). 582–597. 3 indexed citations
11.
Zattarin, Emma, Sara Manglaviti, Laura Mazzeo, et al.. (2022). Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapy. Future Oncology. 18(23). 2593–2604. 3 indexed citations
12.
13.
Toma, Alessandro De, Giuseppe Lo Russo, Diego Signorelli, et al.. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology. 160. 103299–103299. 5 indexed citations
14.
Ferrara, Roberto, Diego Signorelli, Claudia Proto, et al.. (2021). Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. Translational Lung Cancer Research. 10(6). 2955–2969. 6 indexed citations
15.
Occhipinti, Mario, Marta Brambilla, Giulia Galli, et al.. (2021). Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors. Journal of Personalized Medicine. 11(5). 424–424. 8 indexed citations
16.
Prinzi, Natalie, Roberta Rossi, Claudia Proto, et al.. (2020). Recent Advances in the Management of Typical and Atypical Lung Carcinoids. Clinical Lung Cancer. 22(3). 161–169. 15 indexed citations
17.
Ferrara, Roberto, Francesco Facchinetti, Giuseppina Calareso, et al.. (2020). 1278P Hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) as single agent or in combination with platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients (pts). Annals of Oncology. 31. S826–S826. 7 indexed citations
18.
Boeri, Mattia, Massimo Milione, Claudia Proto, et al.. (2019). Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clinical Cancer Research. 25(7). 2166–2173. 64 indexed citations
19.
Bidoli, Paolo, Rita Chiari, Annamaria Catino, et al.. (2016). Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy. Annals of Oncology. 27. vi425–vi425. 18 indexed citations
20.
Filardi, Pasquale Perrone, et al.. (2010). Implementation of cardiovascular secondary prevention guidelines in clinical practice: A nationwide survey in Italy. Nutrition Metabolism and Cardiovascular Diseases. 22(2). 149–153. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elizabeth Dudnik Breakdown of academic impact, for papers by Abdul Rafeh Naqash Breakdown of academic impact, for papers by Florian Kocher Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Motohiro Tamiya Breakdown of academic impact, for papers by Hazem El‐Osta Breakdown of academic impact, for papers by Sung Hoon Sim Breakdown of academic impact, for papers by Sukhbinder Dhesy‐Thind Breakdown of academic impact, for papers by Aurélien Gobert
Rankless by CCL
2026